Akebia Ther (AKBA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $131.67M
Last updated: Nov 17, 2026 at 11:04 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 41.0% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 35.0, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about AKBA
GNG News
All AKBA news- AKBAWestPark Capital starts coverage of Akebia Ther (AKBA) at Buy
UpdatedHistorical
News
AKBA Valuation
Akebia Ther (AKBA) trades at 24.6x forward earnings.
- Forward P/E
- 24.6x
- P/FCF
- 9.0x
- P/B
- 6.1x
AKBA Profitability: Margins, ROIC and FCF
Akebia Ther (AKBA) has a gross margin of 78.9%, an operating margin of -10.2% and a net margin of -22.6%. It posts -38.9% ROIC and a 7.0% FCF margin.
- Gross margin
- 78.9%
- Operating margin
- -10.2%
- Net margin
- -22.6%
- ROIC
- -38.9%
- ROE
- -143.8%
- FCF margin
- 7.0%
- FCF yield
- 11.2%
Akebia Ther Competitors
The companies most similar to Akebia Ther (AKBA) include Anika Therapeutics, Cardiol Therapeutics Inc Class A and Journey Medical.
Sector: Healthcare
Companies most similar to Akebia TherAKBA Analyst Ratings
Akebia Ther (AKBA) has a Buy consensus from 6 analysts: 5 Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 6
- Strong Buy
- 1
- Buy
- 4
- Hold
- 1
- Sell
- 0
- Strong Sell
- 0
AKBA Bull Case vs Bear Case
Bull case
- 83.3% of AKBA's analyst ratings are Buy or Strong Buy.
Bear case
- AKBA has a -22.6% net profit margin.
- AKBA's quarterly revenue changed -37.2% year over year.
- AKBA has a debt-to-equity ratio of 2.5x.
AKBA Earnings: Beat Rate and Next Report
Akebia Ther (AKBA) beat the EPS estimate in 4 of the last 8 quarters (50.0%). Its next report is expected on Feb 24, 2027.
- Beat rate
- 4 of 8 quarters (50.0%)
- Average surprise
- 42.3%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.04
AKBA Earnings Date
AKBA reports Feb 24, 2027. The date is estimated.
AKBA Earnings Call
The latest AKBA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptAKBA ETF Holders
GNG tracks 9 ETFs that hold AKBA. The largest weights:
- iShares Russell 2000 ETF (IWM), 0.03% of the fund
- Fidelity Enhanced Small Cap Core ETF (FESM), 0.02% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
- Vanguard Extended Market Index Fund ETF Shares (VXF), 0.01% of the fund
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About AKBA
When does AKBA report earnings?
Akebia Ther (AKBA) is expected to report earnings on Feb 24, 2027.
Does AKBA pay dividends?
Akebia Ther (AKBA) does not currently pay a regular dividend.
What is AKBA's market cap?
Akebia Ther (AKBA) has a market capitalization of $131.67M with a current stock price of $0.45.
AKBA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.